• Regeneron entered radiopharma collaboration with Telix to co-develop, co-commercialize next-generation radiopharmaceutical therapies under 50/50 cost and profit-sharing model.
• Telix will receive USD 40 million upfront for four initial therapeutic programs.
• Regeneron holds option to add four more programs in exchange for additional upfront payments.
• Telix can opt out of co-funding for a program to pursue up to USD 535 million in milestones, with low double-digit royalties on net sales.
• Parties will also develop diagnostic assets, with Telix leading commercialization and Regeneron receiving set percentage of profits.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Regeneron Pharmaceuticals Inc. published the original content used to generate this news brief on April 13, 2026, and is solely responsible for the information contained therein.